ALLUVI: A COMPREHENSIVE DIVE INTO THE RETATRUTIDE'S PROSPECTS

Alluvi, previously BI 4744, offers a significant breakthrough in weight control treatment. This dual activator targeting both GLP-1 and GIP targets demonstrates impressive results in clinical trials, arguably exceeding existing GLP-1 site stimulators. Early data suggest considerable {weight reduc